Recurring questions
PT-141 questions
A few recurring questions from a development story that changed direction more than once.
Why two names: PT-141 and bremelanotide?
Yes. PT-141 is the research designation and bremelanotide is the medicine name for the same molecule. It is a synthetic cyclic heptapeptide: seven amino acids joined into a ring. The early pharmacology paper describes its melanocortin activity.
Is PT-141 FDA-approved?
Bremelanotide injection received FDA approval in June 2019 for acquired, generalized HSDD in premenopausal women. The first-approval review describes that milestone, and the label defines the indication. Men, postmenopausal women and sexual-performance enhancement fall outside the approval. Compounded PT-141 is not FDA-approved, and laboratory research material is outside the approved finished product.
Does PT-141 work through the brain or blood flow?
Its sexual effects are associated with central melanocortin pathways involving MC4R and MC3R. The mechanism research concerns brain signaling tied to motivation and arousal. Sildenafil and tadalafil act on vascular smooth muscle to support erectile blood flow. The combination study with sildenafil explored those different mechanisms together; it does not establish an approved male indication.
How did desire change in RECONNECT?
The RECONNECT trials found modest improvements in desire and distress over 24 weeks in 1,267 premenopausal women with HSDD. I think the actual score differences are more informative than a general verdict that it works. Tolerability belongs in the same discussion: nausea was prominent in the longer follow-up.
What about PT-141 for men?
Early studies measured erections in healthy men and men with erectile dysfunction, including the intranasal study and subcutaneous research. Those early findings have not established an FDA-approved male use. Later approval followed the female HSDD program. The research page compares these early male experiments with the later trials in women.
Reported duration
The label gives a terminal half-life of approximately 2.7 hours after subcutaneous administration. A separate brain-imaging study measured increased desire for up to 24 hours in women with HSDD. Half-life and duration explains the different measurements; neither gives a guaranteed individual window.
Does PT-141 nasal spray work?
The early male nasal-spray study recorded an erectile response. The program was discontinued because of variability in the amount reaching blood, and the approved route became subcutaneous. An old experimental formulation remains an old experimental formulation.
What is the PT-141 dosage?
The dose-finding page follows the comparisons that led to the 1.75 mg amount in the prescribing information. It reports study and label amounts with their populations and restrictions. Selecting treatment for an individual requires clinical assessment.